0.59
3.33%
+0.019
After Hours:
.5901
0.000100
+0.02%
Biomerica Inc. stock is currently priced at $0.59, with a 24-hour trading volume of 88,596.
It has seen a +3.33% increased in the last 24 hours and a -27.24% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $0.5862 pivot point. If it approaches the $0.6236 resistance level, significant changes may occur.
Previous Close:
$0.571
Open:
$0.56
24h Volume:
88,596
Market Cap:
$9.92M
Revenue:
$5.50M
Net Income/Loss:
$-6.08M
P/E Ratio:
-1.18
EPS:
-0.5
Net Cash Flow:
$-5.30M
1W Performance:
-6.36%
1M Performance:
-27.24%
6M Performance:
-37.23%
1Y Performance:
-55.97%
Biomerica Inc. Stock (BMRA) Company Profile
Name
Biomerica Inc.
Sector
Industry
Phone
949 645 2111
Address
17571 Von Karman Avenue, Irvine, CA
Biomerica Inc. Stock (BMRA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Nov-10-20 | Initiated | Colliers Securities | Buy |
Jan-04-18 | Initiated | B. Riley FBR, Inc. | Buy |
Biomerica Inc. Stock (BMRA) Latest News
Biomerica and Leading UAE Healthcare Company Forge a Path to Enhanced Colorectal and Breast Screening with Exclusive Multi-Year Distribution Agreement
GlobeNewswire Inc.
Biomerica provides update on inFoods® IBS expansion
GlobeNewswire Inc.
Biomerica Reports Third Quarter 2024 Financial Results
GlobeNewswire Inc.
Biomerica InFoods IBS Data to be Presented at the Upcoming Digestive Disease Week (DDW) 2024 Conference
GlobeNewswire Inc.
Diagnostics Industry Leader Gary Huff Appointed to Biomerica Strategic Advisory Board
GlobeNewswire Inc.
Diagnostics Industry Leader Jack Kenny Appointed as Chairman of the Board at Biomerica
GlobeNewswire Inc.
Biomerica Inc. Stock (BMRA) Financials Data
Biomerica Inc. (BMRA) Revenue 2024
BMRA reported a revenue (TTM) of $5.50 million for the quarter ending November 30, 2023, a -65.80% decline year-over-year.
Biomerica Inc. (BMRA) Net Income 2024
BMRA net income (TTM) was -$6.08 million for the quarter ending November 30, 2023, a -9.35% decrease year-over-year.
Biomerica Inc. (BMRA) Cash Flow 2024
BMRA recorded a free cash flow (TTM) of -$5.30 million for the quarter ending November 30, 2023, a -10.75% decrease year-over-year.
Biomerica Inc. (BMRA) Earnings per Share 2024
BMRA earnings per share (TTM) was -$0.38 for the quarter ending November 30, 2023, a +11.63% growth year-over-year.
About Biomerica Inc.
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; Helicobacter pylori test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
Cap:
|
Volume (24h):